How do bamlanivimab and REGN-CoV-2 work?: ‘Both antibody treatments are designed to block the SARS-CoV-2 spike protein and thus prevent the virus from attaching to and entering human cells. These identical so-called monoclonal antibodies are lab-engineered and designed to attack one specific virus in one distinct way.
‘Bamlanivimab contains one monoclonal antibody. REGN-CoV-2, in contrast, consists of two monoclonal antibodies. US pharma company Regeneron says its antibody cocktail lowers the viral load, which helps symptoms dissipate more quickly.
‘The advantage of Regeneron's drug cocktail is that by containing two antibodies, it increases the chance that at least one of them will prove effective during treatment, virologist Sandra Ciesek told German public broadcaster NDR.’
Read here (DW, Jan 29, 2021)
